MSH3 rs1650697: Understanding This Genetic Variant
The rs1650697 variant is a single nucleotide polymorphism located within the MSH3 gene, which plays a critical role in the body's DNA mismatch repair system. Research has investigated this variant for its potential associations with individual sensitivity to certain chemotherapy regimens, though the clinical evidence remains limited.
What each genotype means
Potential altered drug sensitivity
This genotype represents the variant form of the MSH3 gene. Research suggests this variant may be associated with differential sensitivity to certain fluoropyrimidine- and platinum-based chemotherapy regimens. Please discuss your specific treatment plan and potential medication dosing with your clinician or pharmacist.
This genotype is common, with the minor allele frequency for this variant reaching approximately 0.48 globally and exceeding 0.80 in South Asian populations.
Potential altered drug sensitivity
As a carrier of both the reference and variant alleles, your genetic profile for this MSH3 marker is heterozygous. Studies indicate that this variant may influence how your body responds to specific chemotherapy treatments, such as fluoropyrimidines or platinum-based drugs. You should consult with your healthcare provider or pharmacist regarding how this information may relate to your clinical care.
This genotype is frequently observed across diverse populations, consistent with the high global prevalence of the variant allele.
Typical MSH3 genotype
This genotype represents the reference sequence for this MSH3 variant. There is no evidence suggesting this specific configuration contributes to the altered drug sensitivity observed with the variant allele. Always consult your clinician or pharmacist regarding any concerns about medication response or treatment efficacy.
This genotype is common in many populations, though its frequency varies significantly depending on ancestral background.
What is rs1650697?
The variant rs1650697 is a specific genetic change located on chromosome 5 within the MSH3 gene. In genetic terms, it is a missense mutation, meaning the change in the DNA sequence results in a different amino acid being incorporated into the protein structure. Specifically, this variant is known as p.Ile79Val, where an isoleucine is replaced by a valine at position 79 of the MSH3 protein. Because this change occurs in the coding region of the gene, scientists have studied whether it alters the function of the resulting protein. This variant is often discussed in the context of pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to medications. While it is a well-documented site in the human genome, it is important to note that having this variant does not inherently indicate a health condition, but rather represents a common point of natural genetic variation among humans.
The Role of the MSH3 Gene
The MSH3 gene provides instructions for making a protein that is essential for the DNA mismatch repair (MMR) system. This system acts like a biological spell-checker, identifying and correcting errors that occur when DNA is copied during cell division. MSH3 functions by forming a complex with another protein, MSH2, to create a structure known as MutS beta. This complex is specifically responsible for recognizing and repairing larger loops of mismatched DNA. When the mismatch repair system functions correctly, it helps maintain genomic stability and prevents the accumulation of mutations that could lead to cellular dysfunction. Because of its role in maintaining DNA integrity, the MSH3 gene is a subject of significant interest in cancer research. Defects in the MMR pathway can lead to increased mutation rates, which is why researchers study how variations in these genes might influence how cells respond to DNA-damaging agents, including certain types of chemotherapy.
Research and Clinical Associations
Current research into rs1650697 has primarily focused on its potential role in pharmacogenomics, particularly regarding sensitivity to fluoropyrimidine- and platinum-based chemotherapy regimens. Some studies have explored whether this variant influences how effectively these drugs work or how patients experience side effects. However, the evidence supporting a direct clinical impact for this specific SNP is currently classified as limited. While some observational studies have suggested associations between MSH3 variants and treatment outcomes, these findings are not yet robust enough to guide standard clinical practice. It is essential to understand that genetic associations observed in research settings do not always translate into predictable clinical outcomes for every individual. The complexity of cancer treatment involves many factors, including the tumor's specific biology, the patient's overall health, and other genetic markers. Consequently, this variant is not currently used as a standard diagnostic tool for determining chemotherapy dosing or drug selection.
Population Frequency
Genetic variants like rs1650697 are distributed differently across various global populations. Data from large-scale genomic projects indicate that the minor allele frequency for this variant is approximately 0.48 globally. However, this frequency is not uniform; it is notably higher in certain groups, with frequencies exceeding 0.80 in some South Asian cohorts. These differences highlight the importance of considering ancestry when interpreting genetic data. Because the frequency of the variant varies significantly by population, what is considered a 'common' genotype in one part of the world may be less frequent in another. Understanding these population-level patterns is a fundamental aspect of genomic research, as it helps scientists account for natural human diversity when studying the potential effects of specific genetic markers on health and drug response.
What This Means for You
If you have learned that you carry the rs1650697 variant, it is important to view this information in the proper context. This variant is a common genetic feature and is not a diagnostic indicator of disease. While it has been studied for its potential role in how the body processes certain medications, the current scientific evidence is not sufficient to make specific medical recommendations based on this genotype alone. You should never use genetic information to make decisions about your medical care, such as changing or stopping a prescribed medication, without consulting your healthcare provider. If you are concerned about how your genetics might influence your response to a specific treatment, the best course of action is to discuss this with your clinician or a pharmacist. They can provide guidance based on your full medical history, current clinical guidelines, and the most reliable, peer-reviewed evidence available.
How common is this variant?
The minor allele frequency for rs1650697 is approximately 0.48 globally, with frequencies exceeding 0.80 in South Asian cohorts.
Frequently asked questions
Is rs1650697 a sign of cancer risk?
No, rs1650697 is a common genetic variant and is not a diagnostic marker for cancer. While the MSH3 gene is involved in DNA repair, this specific variant is primarily studied in the context of pharmacogenomics rather than as a direct cause of disease.
Should I change my medication based on my MSH3 genotype?
No. You should never change or stop any medication based on genetic test results without consulting your doctor. Genetic associations with drug response are complex and require professional clinical interpretation.
Where can I find more information about MSH3?
You can find reliable information about the MSH3 gene and its functions through resources like MedlinePlus Genetics or the NCBI Gene database. These platforms provide comprehensive, peer-reviewed summaries of human genes.
Why is the frequency of this variant different in South Asian populations?
Genetic variation is naturally distributed across different human populations due to historical migration and evolutionary factors. It is common for certain alleles to be more or less frequent in specific ancestral groups.
Sources & further reading
Educational information only, last refreshed 9/23/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1650697?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29